PhRMA — Pharmaceutical Research and Manufacturers of America
institution
The drug industry's top lobby spent nearly $13 million in three months to shape the rules that govern it.
Who they are
PhRMA, the pharmaceutical industry's leading lobbying group.
What they do
It's the money engine behind the drug industry's influence over federal health regulation.
How it works
PhRMA spent a record $12.9M in just the first quarter of 2025 on federal health policy; combined with the hospital industry's $116.13M in 2024 lobbying, this funding pushes drug-approval reauthorizations toward industry priorities like lower evidence standards and faster approvals.
Why it matters
It shows the financial muscle that lets the industry help write the rules the FDA uses to regulate it.
The engine's record — word for word
Pharmaceutical industry's top lobbying group. Spent record $12.9M in Q1 2025 alone on federal health policy via Roberti Global + similar firms. Combined with hospital industry's $116.13M federal lobbying spend (2024) — the regulatory-capture financial substrate. Ensures PDUFA reauthorizations consistently favor industry priorities (reduced evidentiary standards, shortened approval times, increased industry involvement in FDA decisions).
Follow the trail
Walk this on the live map →